Two MDL Judges in High-Profile Cases, Alarmed by Unfiled Claims, Order Plaintiffs’ Firms to File Lawsuits

Trending Topic: Multidistrict Litigation Faces Scrutiny Over Case Management and Transparency

Charleston, SC – August 21, 2025 – In a rare move, two federal judges overseeing high-profile multidistrict litigation (MDL) cases have issued orders compelling plaintiffs’ law firms to file lawsuits for thousands of unfiled claims, citing concerns over transparency and case management. U.S. District Judge Richard Gergel in South Carolina and U.S. District Judge M. Casey Rodgers in Florida, presiding over MDLs involving PFAS contamination in drinking water and Depo-Provera birth control, respectively, have taken action to address what they describe as significant delays in formalizing claims. The orders, reported by Law.com on August 21, 2025, highlight the complexities of managing large-scale MDLs and the judiciary’s push for accountability.

The PFAS litigation, centered in the District of South Carolina, addresses personal injury and environmental claims related to “forever chemicals” in drinking water, with Pfizer’s counsel alerting Judge Gergel to tens of thousands of unfiled claims. Similarly, in the Northern District of Florida, Judge Rodgers expressed alarm over unfiled claims in the Depo-Provera MDL, which involves allegations of health risks associated with the injectable contraceptive. Both judges issued 21-day deadlines for plaintiffs’ firms to file these claims, with Rodgers threatening to remove non-compliant lawyers from leadership roles in the MDL.

Unfiled Claims Spark Judicial Concern

MDLs, designed to streamline complex cases with common questions of fact under one court, are governed by the Judicial Panel on Multidistrict Litigation (JPML) under 28 U.S.C. § 1407. The process consolidates pretrial proceedings to enhance efficiency, but unfiled claims—cases held by law firms but not yet formally filed in court—can complicate case management. Law professor Teddy Rave noted that while plaintiffs have the prerogative to decide when to file, MDL judges like Gergel and Rodgers require a clear understanding of the “universe of cases” to manage dockets effectively and facilitate potential settlements.

In the PFAS MDL, the sheer volume of unfiled claims raised concerns about the scope of the litigation, potentially involving tens of thousands of plaintiffs alleging exposure to toxic chemicals. The Depo-Provera MDL, meanwhile, focuses on claims of side effects, with unfiled cases risking delays in discovery and resolution. Both judges emphasized the need for transparency to ensure consistent rulings and progress toward bellwether trials, which test key issues to guide broader settlements.

Balancing Efficiency and Plaintiff Rights

The orders have sparked debate within the legal community. Some plaintiffs’ attorneys argue that rushing to file claims could strain resources and force premature litigation, potentially weakening cases. Others, however, view the judges’ actions as necessary to prevent firms from holding claims indefinitely, a practice that can delay justice for plaintiffs and hinder global settlement negotiations. The use of plaintiff fact sheets, a common MDL tool, may help streamline the process by standardizing information about unfiled claims, as outlined by the Federal Judicial Center.

Posts on X reflect mixed sentiments, with some users praising the judges’ proactive approach to case management, while others express concern over pressure on plaintiffs’ firms to meet tight deadlines. These discussions highlight the broader tension between judicial efficiency and the rights of individual plaintiffs in mass tort litigation.

Implications for MDL Practices

The actions of Judges Gergel and Rodgers signal a growing judicial emphasis on accountability in MDLs, which now account for nearly half of federal civil cases. The orders could set a precedent for how MDL judges address unfiled claims, potentially influencing future cases involving mass torts like product liability or environmental contamination. As the PFAS and Depo-Provera MDLs progress, the outcomes of these filings may shape settlement strategies and the broader landscape of multidistrict litigation.

With deadlines looming, plaintiffs’ firms face intense pressure to comply, while the legal community watches closely for how these high-profile cases will redefine MDL management. The judges’ insistence on transparency underscores the judiciary’s commitment to balancing efficiency with fairness in one of the most complex areas of federal litigation.

Sources: Law.com, MotleyRice.com, FJC.gov, GMULawReview.org